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Objective
The purpose of this presentation was to describe the
technical aspects of insertion of MammoSite Radiation
Therapy System (RTS), errors and pitfalls of which
a practicing breast surgeon should be aware, importance
of cosmetic issues, patients selection for the procedure
and satisfaction.
Materials and methods
The patient population consisted of 70 patients who during the
period of 6/2002 – 6/2003 underwent brachytherapy after
insertion of the MammoSite catheter and received a boost HDR
(High Dose Radiation) totaling 1500 cGray in six (6) fractions
over the three (3) day period (250 cGray twice a day). Each
patient then received five (5) weeks of ERT (External beam
Radiation Treatment) to the whole breast. Only T1-2 patients
were treated, including DCIS and invasive carcinomas. No
patient with Tu >3cm was included in this series. Each patient
had computed tomography scanning before initiation of treat-
ment. 3D planning system was used for analysis of dosimetry,
balloon diameter and symmetry, and proximity to the chest wall
and the skin.
M a m m o s i t e  i m p l a n t a t i o n :
(Tunneling)
– Best at the time of lumpectomy.
– Post lumpectomy an option, but N0 later than ten (10) weeks
after.
– Entry Site: lateral to lumpectomy, best through inframammary
fold (most comfortable for patients, post explantation scar is
not seen). Avoid scar entry technique.
– 1st step: lumpectomy cavity is created.
– Trocar is used to create a pathway to cavity (see illustration).
A long acting anesthetic is used to infiltrate the skin and
future catheter tunnel.
– Caution: Avoid proximity of external mammary lymphatics
(lateral thoracic and intercostal brachial distribution, less
painful and less seroma formation was observed).
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A i m.  To describe the technical aspects of insertion of MammoSite Radiation System, cosmetic issues, patients selection for
the procedure and their satisfaction.
M a t e r i a l  a n d  m e t h o d s.  Seventy patients underwent brachytherapy  after insertion of the MammoSite catheter and
received a boost HDR totaling 1500 cGy in six fractions over a three day period. Each patient  then received 5 weeks of external
beam radiotherapy to the whole breast. Only  T1-2 patients were treated.
R e s u l t s.  All patients had excellent cosmetic results. The complications (minimal skin erythema,  hematoma, balloon
leak, seroma, were minimal.
C o n c l u s i o n.  The safety and effectiveness of the MammoSite Radiation Therapy System as a replacement for whole
breast irradiation in the treatment of breast cancer has not yet been established.
System MammoSite w brachyterapii piersi
C e l. Przedstawienie technicznych aspektów zak∏adania systemu MammoSite, ocena wyniku estetycznego, dobór pacjentów
i ich ocena leczenia.
M a t e r i a ∏  i m e t o d y. Siedemdziesiàt chorych (T1-2) poddano brachyterapii po wprowadzeniu cewnika MammoSite – bo-
ost HDR 1500 cGy w szeÊciu frakcjach przez 3 dni. Nast´pnie ka˝da z pacjentek otrzyma∏a napromienianie z pól zewn´trznych
ca∏ej piersi.
W y n i k i. U wszystkich chorych uzyskano bardzo dobry wynik estetyczny. Ma∏o istotne powik∏ania (przejÊciowy rumieƒ skó-
ry, krwiak, przeciek balonika cewnika) nie mia∏y ujemnego wp∏ywu na ocen´ sposobu leczenia.
W n i o s e k. Niezale˝nie od dobrej oceny we wczesnym okresie, bezpieczeƒstwo i skutecznoÊç brachyterapii systemem
MammoSite jako alternatywy dla napromieniania ca∏ej piersi nie jest jeszcze okreÊlone i wymaga dalszych badaƒ.
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– A trocar should be going underneath a deep layer of
superficial fascia through the retromammary bursa (a space
between pectoralis major fascia and deep layer of superficial
fascia). The tip is delivered in the center of lumpectomy cavity.
With this technique the MammoSite catheter is not exposed to
excessive movements and possible dislocation, since bursa
contributes to the mobility of the entire breast and a "sleeve
like" space is being created. Additionally, patients are more
free to move arms.
– Uninflated MammoSite (previously tested for leaks) is
advanced into the cavity trough the trocar path.
– MammoSite is inflated to required volume.
– CT images confirm the adequate position.
– IR192 (Irridium) source is delivered into MammoSite and
RT is delivered as per the treatment plan.
– Explantation after the last treatment – simple (patients are
given Fentanyl 200mcg Lollipop 5 mins before).
– Closure of the entry site optional.
Te c h n i c a l  i s s u e s  i n  m a m m o s i t e  p l a c e m e n t :
– Specimen volume can be determined by measuring its
displacement of water immediately after removal.
– Tumor cavity dimension can be measured at the time of
surgery (with the help of ultrasound).
– If delayed placement of catheter (margin confirmation
uncertain, or MammoSite is unavailable), the procedure can
be done under the ultrasound or CT guidance with the
balloon inflated under local anesthesia. CT images are
obtained to confirm a catheter position, diameter, symmetry
and the proximity to skin and chest wall.
Results
All patients had excellent cosmetic results. In two (2)
patients minimal skin erythema was observed. One (1)
patient developed a hematoma before the last treatment
(drainage & continuation of treatments). Two (2) patients
had balloon leak and required catheter replacement. Nine
(9) patients developed post Brachytherapy seroma
(aspirated).
Discussion
Conventional RT after lumpectomy consists of five (5)
weeks of daily ERT of the whole breast followed by 1-2
weeks of boost to the tumor bed. Acceleration of
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Figure 1. MammoSite brachytherapy catheter
Figure 2. Baloon implanted in lumpectomy cavity
treatment by directing RT to the tumor bed site is being
developed. MammoSite RTS as tumor specific internal
radiation therapy system for BRCA shows invaluable
potential in Brachytherapy for patients with T1-2 disease
and in this study is superior to conventional Multi
Catheter Interstitial Brachytherapy. Specifically, PTV
(Planning Target Volume) is superior with MammoSite,
side effects are minimal and patient's satisfaction
incomparable. FDA approved MammoSite in May 2002
has become an invaluable tool in clinical practice of breast
surgery and radiation. According to international studies,
no statistically significant differences were noted in 5 year
rates of ipsilateral breast treatment failure or loco-
regional failure between conventional ERT and
Brachytherapy patients receiving radiation to the tumor
bed alone over 4-5 days [1, 2]. The MammoSite RTS was
found to be ideal in Brachytherapy application. Long
term efficacy of this treatment approach is not known
and needs further investigation.
At Naples Breast Surgery Center (NBSC), most patients
underwent lumpectomy with or without Sentinel Lymph
Node Biopsy (SLNB) following Stereotactic Localization.
If possible, skin incision is made away from the tumor
site, considering tumor location, size, breast anatomy and
radiological aspects. The tunnel like dissection is carried
out, thus increasing the distance of the balloon from the
skin surface (minium requirement is 5 mm, but preferably
>1 cm). If this distance is not achieved, the balloon is
deflated which usually results in a gain of 2-3 mm in
thickness of the flap overlying the balloon. If this
maneuver still does not help, the skin and subcutaneous
fat overlying the balloon is then excised locally creating
a thicker and satisfactory flap. The same technique
applies to superficially located lesions. In some patients,
because of the suitable anatomical – mammographic
relation, both lumpectomy and lymphatic mapping
including SLNB are performed using the same skin
incision. Superlative cosmetic results and satisfaction
were observed. For the best stability and position of
the catheter and balloon, the tunnel like pathway is
created above the pectoral fascia at the time of lumpec-
tomy. If the cavity of lumpectomy is made larger than
the balloon volume, additional filling of the balloon is
recommended. (The balloons currently available can be
inflated a minimum of 35cc's and a maximum of 125cc's of
volume).
Balloon symmetricalness is critical, otherwise the ra-
diation dose will be uneven and the D90 coverage of 90%
(or more) of PTV will not be achieved [2, 3]. Asymmetry
is seen mainly if the balloon is very close to the chest
wall. It is recommended in these patients to increase the
balloon to maximum volume for a minimum period of
24 hours before deflating the balloon back to the original
volume. In some patients, CT images confirm the
improved symmetry of the MammoSite balloon as a result
of tissue stretching.
At NBSC, if delayed placement of the MammoSite is
considered, #22 Foley Catheter is placed temporarily in
the lumpectomy cavity and it is replaced in 24-48 hours
with a MammoSite inserted under CT guidance.
Side effects and possible complications (rarely seen)
include: skin hyperpigmentation, edema (much less than
interstitial), desquamation, breast pain and tenderness,
seroma (most commonly seen), telangiectasias, ecchy-
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Figure 3. Post implantation CT shows adequate baloon position and symmetry
mosis, drainage around the catheter site (beneficial), fat
necrosis (rare), mastitis, pruritus and blistering.
I n d i c a t i o n s  a n d  p a t i e n t s  s e l e c t i o n s :
– Most T1-2 patients who qualify for breast radiation
are candidates. In the previous trials, patients younger
than 45 and diagnosed with DCIS or ILC were exclu-
ded from the study. At the present time, approximately
26% of all patients diagnosed with DCIS are under-
going MammoSite placement [2, 4].
– Nationwide, of approximately 190,000 patients with
Stage I and II, and DCIS, 120,000 will undergo Breast
Conservation Surgery (BCS).
C o n t r a i n d i c a t i o n s :
– Tumor >3 cm in diameter.
– Lumpectomy cavity too large (also could be a reason
for NOT completing a treatment).
– EIC+.
– Unclear surgical margins.
– Skin spacing < 5 mm, chest wall spacing <1 cm.
– >10 weeks elapsed post lumpectomy.
I m p o r t a n t  c a t h e t e r  h a n d l i n g  p r e c a u t i o n s :
– Careful handling of the MammoSite in the OR envi-
ronment crucial.
– Deflate the balloon completely before closing the
wound.
– No surgical clips or nylon sutures in lumpectomy
cavity.
– Do NOT suture a catheter to the skin.
– Prophylactic antibiotics including topical.
– Patient education and instruction list for catheter care
during brachytherapy is given.
Conclusions
– All patients successfully completed brachytherapy.
– Superb cosmetic outcome was observed in all patients
(100%).
– The safety and effectiveness of the MammoSite RTS
as a replacement for whole breast irradiation in
the treatment of breast cancer has not yet been
established.
Jan Forszpaniak MD, Director
Naples Breast Surgery Center
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Figure 4. Right breast: 3 weeks after brachytherapy
